Amgen (AMGN) Non Operating Interest Expenses (2009 - 2026)

Amgen has reported Non Operating Interest Expenses for 18 years, with the latest figure at $673.0 million in Q2 2026.

• On a quarterly basis, Non Operating Interest Expenses fell 3.03% year-over-year to $673.0 million in Q2 2026; TTM through Jun 2026 was $2.7 billion, a 9.25% decrease from a year earlier, with the FY2025 full-year figure at $2.8 billion, down 12.68% from the prior year.
• Non Operating Interest Expenses was $673.0 million for Q2 2026 at Amgen, up from $657.0 million in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $824.0 million in Q1 2024, with the low at $295.0 million in Q1 2022.
• Average Non Operating Interest Expenses over 5 years is $640.1 million, with a median of $689.5 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Non Operating Interest Expenses surged 129.27% in 2023, then fell 14.11% in 2025.
• Over 5 years, Non Operating Interest Expenses stood at $415.0 million in 2022, then surged by 97.83% to $821.0 million in 2023, then retreated by 9.01% to $747.0 million in 2024, then dropped by 12.58% to $653.0 million in 2025, then advanced by 3.06% to $673.0 million in 2026.
• The last three Non Operating Interest Expenses figures came in at $673.0 million (Q2 2026), $657.0 million (Q1 2026), and $653.0 million (Q4 2025), per Business Quant data.